Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations

Table 1 Cell lines sources and maintenance

Cell line	Source	Media	FBS %	Additives
MCF7	France1	DMEM	10%	1% P/S
1001	France	DMEM	10%	1% P/S
ZR-75-1	Helsinki2	RPMI 1640	10%	1% P/S + Sodium pyruvate (1 mmol/L)
RKO	Horizon3	RPMI 1640	10%	1% P/S + Sodium pyruvate (1 mmol/L)
RKO.p53-/-	Horizon	RPMI 1640	10%	1% P/S + Sodium pyruvate (1 mmol/L)
HCT116	Horizon	RPMI 1640	10%	1% P/S + Sodium pyruvate (1 mmol/L)
HCT116.p53	Horizon	DMEM	10%	1% P/S + 50% F12
HeLa	France	DMEM	10%	1% P/S
MDA-MB-361	France	DMEM	10%	1% P/S
MDA-MB-231	France/ATCC	DMEM	10%	1% P/S + 50% F12 + insulin (10 mg/mL in 25 mmol/L HEPES) + hydrocortisone (0.5 μg/mL)
CAL-51	Helsinki	DMEM	20%	1% P/S
T47D	France	DMEM	10%	1% P/S + 50% F12 + EGF (20 ng/mL)
BT-549	Helsinki	RPMI 1640	10%	1% P/S + Sodium pyruvate (1 mmol/L) + insulin (10 mg/mL in 25 mmol/L HEPES)
SW480	Helsinki	DMEM	10%	1% P/S + 50% F12 + insulin (10 mg/mL in 25 mmol/L HEPES) + hydrocortisone (0.5 μg/mL) + EGF (20 ng/μL)

¹France: Kind Gift from Professor Salem Chouaib, Institute Gustave Roussy, France;

²Helsinki: Kind gift from Professor Paivi peltomaki; Department of Medical Genetics, Helsinki University, Finland;

³Horizon Discovery, Cambridge, United Kingdom.